Is sermorelin FDA approved? the real regulatory answer

Last updated 2026-07-25

Is sermorelin FDA approved right now?

No. There is no FDA-approved sermorelin product on the market today. You can check this yourself in Drugs@FDA, the agency's official database of approved drug products ^[1]. Search sermorelin there and you'll find historical approval records, not a currently marketed, approved drug. That's a different situation from a drug being banned or found unsafe. It's a drug whose approved version was pulled from the market by its maker, for reasons that had nothing to do with safety findings. The gap between "was approved" and "is approved" is exactly where most of the confusion about sermorelin lives, and it's worth sitting with that distinction before you decide anything about treatment.

Was sermorelin ever FDA approved? (the Geref story)

Yes, and this is the part most sermorelin marketing leaves out or gets vague about. A branded synthetic sermorelin acetate product, sold under the name Geref, went through FDA approval in the early 1990s for diagnosing and treating growth hormone deficiency, including a pediatric review documented in a 1999 BioDrugs analysis of its use in children with idiopathic growth hormone deficiency ^[2]. Geref's manufacturer (originally Serono) discontinued the product years later. Discontinued means the company stopped making and selling it, typically for commercial reasons like low sales volume or manufacturing cost, not because FDA revoked approval over a safety signal. A 2006 review in Clinical Interventions in Aging looked at sermorelin's mechanism and clinical rationale for adult growth hormone insufficiency and treated it as a legitimate, previously approved therapeutic option, not a fringe substance ^[3]. This history matters because it separates sermorelin from most of the peptides you'll see discussed alongside it. Compounds like BPC-157 or most GHRPs never went through FDA approval for any indication in the US. Sermorelin did. That's a real regulatory pedigree, even though it doesn't apply to what's sold today.

If sermorelin was approved, why can I still get it?

Because pharmacy compounding is a separate legal track from drug approval, and it's the track sermorelin runs on now. Under 21 U.S.C. 353a, licensed pharmacies can compound a drug for an individual patient with a valid prescription without going through the full FDA new-drug approval process ^[4]. For compounding to be lawful, the active ingredient generally has to appear on FDA's list of bulk drug substances that can be used under section 503A, or be compounded by an outsourcing facility under the parallel 503B bulks list ^[5][6]. FDA keeps a running list of substances nominated for 503A compounding use, and sermorelin has been part of that nomination and evaluation process ^[7]. This is why you'll get a prescription and a compounded vial from a pharmacy rather than a manufacturer-sealed, FDA-approved box off a shelf. It's legal. It's also a fundamentally different quality and oversight system than what applied to Geref, and you should know which system you're buying into.

Compounded sermorelin vs FDA-approved Geref: what actually changed?

The molecule is the same idea, a synthetic analog of growth hormone releasing hormone. What changed is who verifies it and how.

What does the FDA-approved 'intended use' framework mean for sermorelin?

FDA's own regulation on intended use, 21 CFR 201.128, defines it partly by "the circumstances that the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised" ^[8]. In plain terms, a drug's approved status is tied to a specific labeled use, more than the molecule floating around in commerce. Geref was approved for diagnosing and treating growth hormone deficiency, a defined medical condition confirmed by testing. It was not approved as a general wellness, anti-aging, or performance product, and no FDA-approved sermorelin product exists for those uses today either. If a clinic markets sermorelin for muscle gain, fat loss, or reversing aging in adults with normal GH levels, that's outside anything FDA ever evaluated for this compound, approved or compounded.

Is sermorelin legal to prescribe if it's not FDA approved?

Yes, prescribing compounded sermorelin is legal in the framework Congress built specifically for this situation. Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, exempts compounded preparations from the new-drug-approval and FDA-approved-labeling requirements when a licensed pharmacist compounds based on a valid prescription for an identified patient ^[4]. The catch is that this exemption depends on real conditions being met: a genuine prescription, an individual patient, and (generally) an active ingredient that's on or has cleared review for the applicable bulks list ^[5][7]. A pharmacy mass-producing sermorelin without individual prescriptions, or using an ingredient not cleared for compounding, would fall outside that protection. This is a big part of why sourcing matters so much with peptides generally, something covered in more detail on the sermorelin overview page.

Is sermorelin the same as HGH, and does approval status change that comparison?

No, and this is the comparison most people actually came here to understand. Sermorelin is a growth hormone releasing hormone (GHRH) analog. It signals your own pituitary gland to make and release growth hormone. HGH (somatropin) is the growth hormone itself, injected directly. That mechanism difference has real consequences. Because sermorelin depends on a working pituitary, it can't push GH output past what your gland is physiologically able to produce, whereas injected HGH bypasses that ceiling entirely. A 2020 review in Translational Andrology and Urology on growth hormone secretagogues in hypogonadal men and a 2017 study in the American Journal of Men's Health both looked at GH secretagogue treatment raising serum IGF-1 levels in hypogonadal men, describing a real but generally more moderate hormonal effect than direct GH administration ^[9][10]. HGH itself has multiple FDA-approved formulations on the market right now for defined conditions like confirmed growth hormone deficiency, and you can verify current approved products directly in Drugs@FDA ^[1]. Sermorelin does not have that same live approved status. If your prescriber's actual goal is maximum, reliable, dose-controlled GH elevation, HGH is the more direct and more thoroughly regulated tool. Sermorelin's case is different: it works with a slower, self-limited mechanism that some prescribers prefer specifically because it can't overshoot your gland's own ceiling, but it is the physiologically gentler and less potent option, not a drop-in substitute. For a side-by-side against another oral secretagogue option, see mk 677 vs sermorelin.

Does lack of FDA approval mean sermorelin is unsafe?

Not by itself, no. Approval status and safety data are related but separate questions. Sermorelin's core mechanism, as a GHRH analog with a known peptide sequence, has been studied clinically for decades, including work on its use in growth hormone deficiency diagnosis and treatment ^[2][3]. What lack of current FDA approval does mean is that no manufacturer is currently required to run FDA-mandated batch testing, stability studies, or post-market surveillance on a specific commercial sermorelin product, because no such product currently exists in FDA's approved catalog. That oversight gap gets filled, imperfectly, by state pharmacy boards and by individual compounding pharmacies' own quality practices, which vary. A 2016 paper in Drug Testing and Analysis documenting falsified biopharmaceutical injectables circulating in Europe is a reminder that the injectable peptide supply chain broadly has real quality control failure points worth taking seriously, even if that specific study wasn't about sermorelin itself ^[11]. Buy through a licensed pharmacy with a real prescription, not a gray-market supplier.

How is sermorelin actually dosed if there's no approved label to follow?

Without a current FDA-approved label, dosing follows clinical convention built from the historical Geref labeling and prescriber experience rather than a single fixed federal standard. Typical protocols use subcutaneous injection once daily, usually at night, timed around the body's natural GH pulse pattern. Because there's no approved label locking in exact numbers, your actual dose, injection frequency, and cycle length will come from your prescriber's judgment and the compounding pharmacy's formulation, and these can genuinely differ between practices. That's worth walking through carefully rather than assuming a one-size protocol. The sermorelin how to inject and sermorelin injection sites pages walk through the practical mechanics, and sermorelin timeline what to expect covers how long people typically stay on it before reassessing.

Are there safety or drug interaction concerns tied to its unapproved status?

The bigger practical risk isn't the molecule itself, it's inconsistent sourcing and inadequate screening. Because there's no FDA-approved label spelling out contraindications for a currently marketed product, that screening burden falls entirely on your prescriber during intake. A 2026 case report in Frontiers in Surgery described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating that GH axis manipulation over extended periods can carry structural risks worth monitoring, even though that case involved GH use rather than sermorelin specifically ^[12]. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides in orthopaedics broadly and flagged ongoing challenges around regulation and evidence quality in this drug class ^[13]. Talk through your full medication list and any history of hormone-sensitive conditions with your prescriber before starting. More detail is on the sermorelin drug interactions page.

Could sermorelin get FDA approved again in the future?

Nothing in current public FDA data points to an active, near-term approval effort for a new branded sermorelin product. Approval status can be checked anytime directly through Drugs@FDA ^[1], and nothing prevents a manufacturer from filing a new application in the future, but that would require running new clinical trials and paying for the full approval process again, since Geref's old approval doesn't just reactivate. Research interest in the compound continues in specific, narrow contexts. A 2021 paper in Annals of Translational Medicine explored sermorelin as a potentially effective drug for patients with recurrent glioma, a completely different application from GH deficiency treatment and still early-stage ^[14]. That kind of research keeps the molecule scientifically relevant, but it doesn't change its current regulatory status as an unapproved, compounded product for GH-related use.

What should you actually check before starting sermorelin?

Confirm three things before you commit: a real diagnosis and lab workup behind the prescription, a licensed pharmacy actually compounding the product, and a prescriber willing to discuss the approval gap honestly rather than glossing over it. Ask directly which pharmacy fills the prescription and whether that pharmacy operates under 503A or 503B rules ^[5][6]. Ask what your labs showed and why sermorelin specifically, rather than HGH, is the right tool for your situation. If a clinic can't or won't answer either question clearly, that's a real warning sign, separate from anything about the compound itself. Sermorelin Co works with providers who review your history and route you to a pharmacy partner operating within this framework, rather than skipping that screening step.

Frequently asked questions

Is sermorelin FDA approved in 2026?

No. There is no currently FDA-approved sermorelin drug product on the market. A branded version called Geref was FDA approved decades ago but the manufacturer discontinued it in 2008. Today's sermorelin comes from compounding pharmacies operating under 21 U.S.C. 353a, which is a legal but separate track from FDA drug approval.

What was Geref and why was it discontinued?

Geref was the branded, FDA-approved synthetic sermorelin acetate product used to diagnose and treat growth hormone deficiency, reviewed in pediatric populations in a 1999 BioDrugs analysis. Its manufacturer discontinued it years later. Discontinuation was a business decision, not an FDA safety action, and it's confirmed by checking Drugs@FDA's approval history.

Is compounded sermorelin legal?

Yes, when a licensed pharmacy compounds it for an individual patient with a valid prescription under 21 U.S.C. 353a. The active ingredient generally needs to be on FDA's 503A or 503B bulk drug substance lists. It's not the same legal category as an FDA-approved drug, but it is a lawful, defined pathway, not a loophole.

Is sermorelin the same thing as HGH?

No. Sermorelin is a GHRH analog that signals your pituitary to release its own growth hormone. HGH (somatropin) is growth hormone itself, given directly. Sermorelin's effect is capped by your pituitary's own capacity; HGH bypasses that ceiling. HGH has current FDA-approved formulations; sermorelin currently does not.

Why doesn't sermorelin have current FDA approval if HGH does?

Sermorelin did have FDA approval as Geref, but that product was discontinued by its manufacturer in 2008. HGH manufacturers have kept approved products actively on the market and maintained their applications. The difference is business continuity and ongoing regulatory maintenance, not a finding that sermorelin failed a safety or efficacy review.

Does unapproved status mean sermorelin is unsafe?

Not inherently. Approval status reflects whether a specific current manufacturer's product went through FDA's premarket review, not whether the molecule itself was ever found dangerous. The real practical risk with unapproved compounded products is inconsistent sourcing and pharmacy quality control, which is why choosing a licensed, reputable compounding pharmacy matters.

How do I check if a specific sermorelin product is FDA approved?

Search Drugs@FDA, the FDA's official database of approved drug products, directly at accessdata.fda.gov. If a product doesn't appear as currently approved and marketed, treat any marketing claim of FDA approval as false. Compounded sermorelin will never show up as an approved product because it isn't one.

Can a doctor legally prescribe sermorelin off-label or through compounding?

Yes. Physicians can prescribe compounded sermorelin under the 21 U.S.C. 353a framework when there's a valid, individualized prescription and a licensed compounding pharmacy fills it. This is standard practice for many compounded medications, not unique to sermorelin, though it does put more responsibility on prescriber judgment than an FDA-approved label would.

Is sermorelin banned in sports or by anti-doping agencies?

GHRH analogs including sermorelin fall under substances that anti-doping labs actively test for using specialized mass spectrometry methods designed to detect these peptides in urine, plasma, and blood samples. Multiple analytical chemistry studies describe building assays specifically to catch GHRH-class peptides, reflecting their prohibited status in tested competitive sport.

What's the difference between 503A and 503B compounding for sermorelin?

503A covers traditional compounding pharmacies preparing patient-specific prescriptions, governed by 21 CFR 216.23's bulks list. 503B covers larger outsourcing facilities that can compound in batches without individual prescriptions in some cases, governed by 21 CFR 216.24's separate bulks list. Both require the active ingredient to be on the applicable approved list.

Does sermorelin's regulatory history make it safer than newer peptides like BPC-157?

It gives sermorelin a real prior approval and decades of documented clinical use that most newer research peptides simply don't have. That's a genuine advantage in understood mechanism and dosing history. It doesn't make current compounded batches automatically safer, since manufacturing oversight today depends on the individual pharmacy, not on the old Geref approval.

Should I choose sermorelin or HGH if I want a GH-boosting treatment?

That depends entirely on your labs and goals, and it's a conversation for a prescriber, not a default choice. Sermorelin works more gradually and only if your pituitary still functions; HGH gives direct, dose-controlled elevation and has current FDA-approved formulations. Neither is proven to reverse aging or boost performance in people with normal GH levels.

Sources

1. FDA, Drugs@FDA database: Official database for checking current FDA drug approval status, including historical Geref sermorelin approval records
2. BioDrugs, 1999 (PMID 18031173): Sermorelin was reviewed as an FDA-approved diagnostic and treatment agent for idiopathic growth hormone deficiency in children
3. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin's mechanism and clinical rationale for managing adult growth hormone insufficiency
4. 21 U.S.C. 353a, pharmacy compounding: Legal basis allowing licensed pharmacies to compound drugs for individual patients under valid prescriptions without full FDA new-drug approval
5. 21 CFR 216.23, the 503A Bulks List: Federal bulk drug substance list that active ingredients must appear on for traditional 503A compounding
6. 21 CFR 216.24, the 503B Bulks List: Separate federal bulk drug substance list governing outsourcing facility compounding under 503B
7. FDA, bulk drug substances nominated for use in compounding: FDA's running list of substances, including sermorelin, nominated and evaluated for compounding use under 503A
8. 21 CFR 201.128, meaning of intended uses: FDA regulation defining a drug's intended use by labeling, advertising, and circumstances of distribution
9. Translational Andrology and Urology, 2020 (PMID 32257855): Review of growth hormone secretagogues' role in body composition management in hypogonadal males
10. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment raised serum IGF-1 levels in hypogonadal men
11. Drug Testing and Analysis, 2016 (PMID 26456392): Documentation of falsified biopharmaceutical injectables circulating in the European supply chain
12. Frontiers in Surgery, 2026 (PMID 42465868): Case report of anterior cervical osteophyte-related dysphagia in a long-term growth hormone user
13. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics noting ongoing regulatory and evidence-quality challenges
14. Annals of Translational Medicine, 2021 (PMID 33842627): Early-stage research exploring sermorelin as a potential treatment for recurrent glioma